Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 10, 2015; 6(5): 744-751
Published online Jun 10, 2015. doi: 10.4239/wjd.v6.i5.744
Published online Jun 10, 2015. doi: 10.4239/wjd.v6.i5.744
Emerging links between type 2 diabetes and Alzheimer’s disease
Gumpeny R Sridhar, Gumpeny Lakshmi, Gumpeny Nagamani, Endocrine and Diabetes Centre, Department of Obstetrics and Gynecology, Andhra Medical College, Visakhapatnam 530002, India
Author contributions: Sridhar GR, Lakshmi G and Nagamani G contributed equally to this paper.
Conflict-of-interest: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gumpeny R Sridhar, MD, DM, FACE, FRCP, Endocrine and Diabetes Centre, Department of Obstetrics and Gynecology, Andhra Medical College, 15-12-15 Krishnanagar, Visakhapatnam 530002, India. sridharvizag@gmail.com
Telephone: +91-891-2566301 Fax: +91-891-2509427
Received: August 29, 2014
Peer-review started: August 30, 2014
First decision: November 27, 2014
Revised: December 4, 2014
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: June 10, 2015
Peer-review started: August 30, 2014
First decision: November 27, 2014
Revised: December 4, 2014
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: June 10, 2015
Core Tip
Core tip: Type 2 diabetes mellitus is a risk factor for future development of Alzheimer’s disease, the most prominent cause of cognitive failure in the elderly. Common pathogenic mechanisms underpin both conditions. Therapeutic strategies in prevention (lifestyle changes) and pharmacological agents (biguanides, intranasal insulin, thiazolidinediones, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors could also be useful against Alzheimer’s disease.